On June 24, 2023, Bellerophon Therapeutics Approved Reduction-In-Force Of Substantially All Of Its Employees, Including Its Executive Officers - Filing
On June 24, 2023, Bellerophon Therapeutics Approved Reduction-In-Force Of Substantially All Of Its Employees, Including Its Executive Officers - Filing
2023年6月24日，Bellerophon Therapeutics批准了包括執行官在內的幾乎所有員工的有效裁員——申報
The determination to effect the workforce reduction was made in connection with the Company's decision to terminate its REBUILD Phase 3 clinical study of INOpulse for the treatment of fibrotic Interstitial Lung Disease ("fILD") and withdraw patients from the Company's ongoing INOpulse development programs.The Company intends to enter into separation and/or transition agreements with each of Peter Fernandes, the Company's Chief Executive Officer, Parag Shah, the Company's Vice President of Business Operations, and Martin Dekker, the Company's Vice President of Engineering and Manufacturing.
裁員的決定與公司決定終止其用於治療纖維化間質性肺病（“FilD”）的InoPulse的重建3期臨床研究以及讓患者退出公司正在進行的InoPulse開發計劃有關。公司打算與公司首席執行官彼得·費爾南德斯、公司副總裁帕拉格·沙阿簽訂分離和/或過渡協議業務運營部副總裁馬丁·德克爾工程與製造。